ARTICLE | Product Development
Anchor ADC in Merck-Kelun deal step closer to China market
Progression-free survival results could lead to submission of rival to TROP2 therapies from Gilead, Daiichi-AZ
August 14, 2023 10:18 PM UTC
The ADC that anchored Merck’s growing relationship with Chinese biotech Kelun has cleared the bar in a Phase III study, propelling the therapy toward a submission in China as the partners advance its global program in multiple cancers.
The results of the study, in which TROP2-targeting antibody-drug conjugate sacituzumab tirumotecan (SKB264/MK-2870) showed a significant progression-free survival benefit over chemotherapy, represent the first Phase III evidence for a therapy that could rival Trodelvy sacituzumab govitecan-hziy from Gilead Sciences Inc. (NASDAQ:GILD) and datopotamab deruxtecan (DS-1062) from Daiichi Sankyo Co. Ltd. (Tokyo:4568) and AstraZeneca plc (LSE:AZN; NASDAQ:AZN)...